Thomas Jefferson University Hospital, Inc.
Locations
Transplant Summary
Overview
The Transplant and Cellular Therapy Program at Thomas Jefferson University Hospital (TJUH) is focused on innovative haploidentical hematopoietic graft engineering research to overcome access disparities and improve patients’ outcomes. The TJUH Cellular Therapy Program offers all FDA approved CAR T therapies and an expanded portfolio of clinical trials such as “off the shelf” allogeneic CAR T, CAR NK and COVID-19 CTLs.This center has been performing allogeneic transplants since 1995 and has been an NMDP transplant center since November 1998.
Attending physicians
Adult - Xia Bi, Joanne Filicko-O'Hara, Usama GergisTransplants performed
Marrow/PBSC and double cordCord blood transplants
Adult onlyPatient survival information for this center
This center's actual 1-year survival results are similar to the expected rate for this center*.The survival information we have for this center includes ONLY:- Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2020, 2021, 2022 and
- Who had their transplant at a U.S. transplant center, and
- Who had follow-up information provided by the transplant center for analysis
For this center, we have survival information for 125 patients.The actual 1-year survival of these patients is 64%.Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 59.6% and 75%.For help with understanding these statistics, please see Understanding Transplant Outcomes.For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report (Opens in a new tab) at bloodcell.transplant.hrsa.gov.* The expected survival rate for a transplant center can be below, similar to, or above the range listed. This is based on comparing patient survival at all centers that treated patients with similar diseases.
The survival rate cannot tell how you will do with your transplant. Talk to your doctor to understand your prognosis or the likely course of your disease.
Total adult transplants
199
Transplants reported by the centers (from January 1, 2022 to December 31, 2023)
Marrow PBSC Cord blood Total AllogeneicRelated donorMarrow0PBSC64Cord blood0Total64Unrelated donorMarrow0PBSC24Cord blood0Total24Total allogeneicMarrow0PBSC88Cord blood0Total88AutologousMarrowBoth marrow & PBSC 111PBSC—Cord blood—Total111Total combinedMarrowBoth marrow & PBSC 199PBSC—Cord blood0Total199All Diseases
Number of transplants by age reported from January 1, 2022 to December 31st, 2023(includes marrow, PBSC and cord blood)
0-18 19-44 45-64 65+ Total Related 0-18019-441045-643265+22Total64Unrelated 0-18019-44545-64765+12Total24Autologous 0-18019-44645-646865+37Total111Total 0-18019-442145-6410765+71Total199Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.
Centers are not required to report autologous transplants so the numbers might be incomplete.
More information about transplants can be found:
- U.S. Transplant Data by Center (Opens in a new tab) report at blood cell.transplant.hrsa.gov
- List of diseases
Transplant center resources
Financial representativeTheresa McNeilPhone: (215) 955-9384NMDP patient navigators
Patient navigators can answer your questions about choosing a transplant center and provide support and education to help you throughout your transplant journey.
- Inside the United States: 1 (888) 999-6743
- Outside the United States: 1 (763) 406-3410. (Long distance or international charges may apply.)
Email: patientinfo@nmdp.org
More resources
- Choosing a transplant center
- Preparing for transplant
- Learn about transplant outcomes and treatment decisions (Opens in a new tab)
- Support and resources (including non-English materials)
- U.S. Transplant Data by Center (Opens in a new tab) at blood cell.transplant.hrsa.gov
Jefferson Health Bone Marrow Transplant & Cellular Therapy Landmark Program
834 Chestnut St.Suite 308 Philadelphia, PA 19107 Phone:215-955-0352 Physician Referrals:215-955-8874 Email:bmtct-qa@jefferson.edu For more information about this program: https://www.jeffersonhealth.org/conditions-and-treatments/bone-marrow-transplant (Opens in a new tab)Overview
BMTCT's Landmark Program is a survivorship program designed to not only help our patients survive, but to thrive. Our program helps patients that have been identified as Landmark candidates to transition into life after transplant by going through each body system and help reach different milestones of health.
Staff
Program Director:Usama Gergis, MD, MBAProgram Coordinator:Michael Dugan, MBAMedical Specialties in Program
Cardiology, dermatology, gastroenterology, general surgery, gynecology, hematology, infectious disease, nephrology, neurology, oncology, ophthalmology/optometry, palliative care, Pathology Radiology, psychiatry/psychology, pulmonology.Medical Services Offered
Chronic GVHD management, fertility counseling, reproductive health, financial counseling, nutrition/dietetics, occupational therapy, pain management, physical therapy and rehabilitation, Primary care and Preventative screening, sexual health, social services, vaccinations.Telemedicine services are available.Patient Eligibility
Adults- Allogeneic and Autologous transplant recipients
- Adults: depending on patient status and physician referral after transplant.
- Adults (over age 18)
- Will provide care to adult patients who underwent transplant as a child
- Does accept patients who were transplanted at another hospital